drugset / Trial / NCT04158687
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily (QD) for 12 weeks to adult participants with schizophrenia on stable dopaminergic antipsychotic medication.
Timeline
- Start
- 2019-11-26
- Primary completion
- 2020-12-22
- Completion
- 2020-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTP-692 | Unknown | 1 g | Oral |
| Subject | CTP-692 | Unknown | 2 g | Oral |
| Subject | CTP-692 | Unknown | 4 g | Oral |